Abstract: Provided is an antibody or an immunologically reactive fragment thereof which targets exclusively an A? having a specific turn structure of A? (a toxic conformer of A?). Also provided are a medicinal composition comprising, as an active ingredient, an antibody that specifically recognizes a toxic conformer of A?, a kit for assaying a toxic conformer of A?, a diagnostic agent for Alzheimer's disease, etc.

Abstract: The present invention provides a method of testing plasma and/or serum of a test subject for determining the pathology or onset risk of acute coronary syndrome, including (1) a step of measuring a soluble amyloid ? precursor protein (sAPP) 770 level of plasma and/or serum of a test subject; and (2) a step of relating the plasma and/or serum sAPP770 level(s) measured in (1) to the pathology or onset risk of acute coronary syndrome.

Abstract: The present invention addresses the problem of providing a novel substance capable of interfering with various functions of integrin ?4, and/or providing a novel substance capable of interfering with both integrin ?4 and integrin ?9. The present invention provides an integrin ?4 mutant peptide having one portion of the extracellular domain of human integrin ?4, and the like, and in concrete terms relates to a peptide and the like having the amino acid sequence of Sequence No. 4 through 9, and a pharmaceutical composition comprising as the active ingredient the same peptide.

Abstract: Provided is a therapeutic method exclusively targeting an amyloid ? protein (A?) having a specific turn structure of A?. Specifically provided is an antibody which specifically recognizes an amyloid ? having a turn structure at amino acids positions 22 and 23. Also provided are a medicinal composition comprising, as the active ingredient, an antibody specifically recognizing a toxic conformer of amyloid ?, an assay kit for a toxic conformer of amyloid ?, a diagnostic for Alzheimer's disease, etc.

Abstract: [PROBLEMS] To provide a technique which enables an effective antibody therapy for cancer which targets for FGFR1 without the need of using any effective antibody having high specificity and a potent cell-killing activity. [MEANS FOR SOLVING PROBLEMS] Disclosed are: a therapeutic agent for cancer, which comprises an enhancer of the expression of a fibroblast growth factor receptor-1 and an anti-fibroblast growth factor receptor-1 antibody; and a method for the treatment of cancer using the therapeutic agent.

Abstract: The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided.

Abstract: Provided is a therapeutic method exclusively targeting an amyloid ? protein (A?) having a specific turn structure of A?. Specifically provided is an antibody which specifically recognizes an amyloid ? having a turn structure at amino acids positions 22 and 23. Also provided are a medicinal composition comprising, as the active ingredient, an antibody specifically recognizing a toxic conformer of amyloid ?, an assay kit for a toxic conformer of amyloid ?, a diagnostic for Alzheimer's disease, etc.

Abstract: The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided.

Abstract: The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided.

Abstract: [Problems] To provide a technique which enables an effective antibody therapy for cancer which targets for FGFR1 without the need of using any effective antibody having high specificity and a potent cell-killing activity. [Means for Solving Problems] Disclosed are: a therapeutic agent for cancer, which comprises an enhancer of the expression of a fibroblast growth factor receptor-1 and an anti-fibroblast growth factor receptor-1 antibody; and a method for the treatment of cancer using the therapeutic agent.

Abstract: Disclosed are: an agent, an apparatus and a method for the diagnosis of a disease associated with the abnormality in ?-secretase; a method for providing information for the diagnosis of a disease associated with the abnormality in ?-secretase; a method for monitoring the condition or the degree of progression of a disease associated with the abnormality in ?-secretase; and a method for determining the therapeutic effect of a therapeutic agent on a disease associated with the abnormality in ?-secretase. More specifically disclosed are: a diagnostic agent for a disease associated with the abnormality in ?-secretase, which comprises an antibody capable of recognizing a digestion product of an alcadein with ?-secretase or ?-secretase or a fragment of the antibody; and others.

Abstract: The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided.